Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin

Cancer Research

Volumn 69, Issue 7, 2009, Pages 3004-3012

  Huang, Min ^a   Itahana, Koji ^b   Zhang, Yanping ^b   Mitchell, Beverly S ^a  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOXORUBICIN; ENHANCED GREEN FLUORESCENT PROTEIN; GUANINE NUCLEOTIDE; GUANOSINE TRIPHOSPHATE; MEMBRANE PROTEIN; NUCLEOLIN; NUCLEOPHOSMIN; NUCLEOSTEMIN; NUTLIN 3; PROTEIN MDM2; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; AVN 944; CARBAMIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; CARRIER PROTEIN; IMIDAZOLE DERIVATIVE; INOSINATE DEHYDROGENASE; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; NUCLEOSTEMIN PROTEIN, HUMAN; PHOSPHOPROTEIN; PIPERAZINE DERIVATIVE; PROTEASOME; RNA BINDING PROTEIN;

ARTICLE; BINDING SITE; CELL NUCLEUS; ENZYME INHIBITION; ENZYME RELEASE; GENE MUTATION; GENE SEQUENCE; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UBIQUITINATION; WILD TYPE; BIOSYNTHESIS; CELL STRAIN K 562; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM;

CARBAMATES; CARRIER PROTEINS; CELL LINE, TUMOR; GUANOSINE TRIPHOSPHATE; HUMANS; IMIDAZOLES; IMP DEHYDROGENASE; K562 CELLS; NUCLEAR PROTEINS; PHENYLUREA COMPOUNDS; PHOSPHOPROTEINS; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 66149142266     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3413     Document Type: Article

References (41)

1. Tsai RY, McKay RD. A multistep, GTPdriven mecha- nism controlling the dynamic cycling of nucleostemin. J Cell Biol 2005;168:179-184
2. Misteli T. Going in. GTP cycles in the nucleolus. J Cell Biol 2005;168:177-178
3. Meng L, Yasumoto H, Tsai RY. Multiple controls regulate nucleostemin. partitioning between nucleolus and nucleoplasm. J Cell Sei 2006;119:5124-5136
4. 4» Meng L, Zhu Q, Tsai RY. Nucleolar trafficking of nucleostemin family proteins: common versus protein- specific mechanisms. MoI Cell Biol 2007;27:8670-8682
5. Huang M,Ji Y, Itahana K, Zhang Y, Mitchell B. Guanine nucleotide depletion inhibits pre-ribosomal RNA syn- thesis and causes nucleolar disruption. Lenk Res 2008; 32:131-141
6. Tsai RY, McKay RD. A nucleolar mechanism control- ling cell proliferation in stem, cells and cancer cells. Genes Dev 2002;16:2991-3003.
7. Han C, Zhang X, Xu W, Wang W, Qian H, Chen Y. Cloning of the nucleostemin gene and its function in transforming human embryonic bone marrow mesen- chymal stem cells into F6 tumor cells. Int J MoI Med 2005;16:205-213
8. Beekman C, Nichane M, De Clercq S, et al. Evolution- arily conserved role of nucleostemin: controlling prolif- eration of stem/progenitor ceUs during early vertebrate development. MoI Cell Biol 2006;26:9291-9301
9. Zhu Q, Yasumoto H, Tsai RY. Nucleostemin. delays cellular senescence and negatively regulates TRFl protein, stability. MoI Cell Biol 2006;26:9279-9290
10. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431-42.
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemother- apy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
12. Shaffer AL, Wright G, Yang L, et al. A library of gene expression, signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006:210: 67-85.
13. Boisvert FM, van Koningsbruggen S, Navascues J, Lomond AI. The multifunctional nucleolus. Nat Rev MoI Cell Biol 2007;8:574-585
14. Mayer C, Grummt I. Cellular stress and nucleolar function. Cell Cycle 2005;4:1036-1038
15. Korgoonkor C, Hagen J, Tompkins V et al. Nucleo- phosmin (B23) targets ARF to nucleoli and inhibits its function. MoI Cell Biol 2005;25:1258-1271
16. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. MoI Cell Biol 2004:24: 985-996
17. JIn A, Itahana K, O'Keefe K, Zhang Y. Inhibition, of HDM2 and activation of p53 by ribosomal protein L23. MoI Cell Biol 2004i24{7669-80.
18. Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein LIl negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. MoI CeU Biol 2003;23:8902-8912
19. Dai MS, Zeng SX, Jin Y, et al. Ribosomal. protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. MoI Cell Biol 2004;24:7654-7668
20. Carroll VA, Ashcroft M. Regulation of angiogenic factors by HDM2 in. renal cell carcinoma. Cancer Res 2008;68:545-552
21. Sidi Y, Hudson JL, Mitchell BS. Effects of guanine ribonucleotide accumulation, on the metabolism, and cell cycle of human lymphoid cells. Cancer Res 1985:45: 4940-4945
22. Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin. activates p53 and induces cell cycle arrest via inhibition of MDM2. MoI Cell BIoI 2008;28:4365-4376
23. Vassllev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MD.M2. Science 2004;303:844-848
24. Lapalombella R, Zhao X, Triantafillou G, et al. A novel Roji-Burkitt's lymphoma model for preclinical and mechanistic evaluation, of CD52-targeted immuno- therapeutic agents. Clin Cancer Res 2008;14:569-578
25. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad ScI U S A 2003;100:13303-13307
26. Katayomo H, Sasai K. Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabili- zatlon. and inhibition of p53. Nat Genet 2004;36:55-62.
27. Lin HK, Wong L, Hu YC, Altuwoijri S, Chang C. Phosphorylation-dependent ubiquitylation and degra- dation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002;21:4037-4048
28. Linke SP, Clarkin KC, Di Leonardo A, !'sou A, Wahl GM. A reversible, p53-dependent G0/G, ceU cycle arrest induced by ribonucleotide depletion in. the absence of detectable DNA damage. Genes Dev 1996;10:934-947
29. Lohrum MA, Ludwig RL, Kubbutat MH, Hanion M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein LIl. Cancer Cell 2003;3:577-587
30. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004;279:44475-44482
31. Dai MS, Zeng SX Jin Y, Sun XX David L, Lu H. Ribosomal. protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. MoI Cell Biol 2004:24: 7654-7668
32. Dai MS, Shi D, Jin Y, et al. Regulation of the MDM2-53 pathway by ribosomal protein LIl involves a post-ubiqultinatlon. mechanism. J Biol Chem 2006:281: 24304-24313
33. Lindstrom MS, Jin A, Deisenroth C, Wolf GW, Zhang Y, Xiong Y. Cancer-associated mutations in MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. MoI Cell Biol 2007;27:1056-1068
34. Lindstrom MS, Deisenroth C, Zhang Y. Putting a finger on growth surveillance: insight into MDM2 zinc flnger-ribosomal protein, interactions. Cell Cycle 2007;6: 434-437
35. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996:56:2649-2654
36. Ma H, Pederson T, Depletion of the nucleolar protein nucleostemin causes Gl cell cycle arrest via the p53 pathway. MoI Biol Cell 2007;18:2630-2635
37. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. MoI Cell 2006;23:251-263
38. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. CeU 2003;112:779-791
39. Doman D, Wertz I, Shimizu H, et al. The ubiquitin ligase COPI is a critical negative regulator of p53. Nature 2004;429:86-92.
40. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF- BPI/Mule is a critical, mediator of the ARF tumor suppressor. Cell 2005;121:1071-1083
41. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends MoI Med 2007;13:23-31.